Latest News - Becton Dickinson
Top Corporates Hub
Becton Dickinson
BSX Stock: Is It Time To Buy Or Sell Puts?
09.09.2026 18:06
Trading near $45 a share, Boston Scientific (BSX) sits roughly 58% below its 52-week peak. Instead of buying the dip outright, selling cash-secured put options allows investors to generate immediate income while locking in an even deeper entry point. Sell a put option on BSX expiring 9/17/2027, with a strike price of $30.
Becton, Dickinson and Company (BDX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
09.09.2026 13:47
Becton, Dickinson and Company (BDX) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:00 AM EDTCompany ParticipantsThomas Polen - President,...
Becton Dickinson & Co's Dividend Analysis
09.09.2026 11:01
Becton Dickinson & Co (NYSE:BDX) recently announced a total dividend of $1.05 per share, with the ex-dividend date set for 2026-09-09. This cash dividend is payable on 2026-09-30. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates.
Becton Dickinson (BDX) Becomes Founding Sponsor Of Hazardous Drug Data Consortium
03.09.2026 03:26
Becton Dickinson (NYSE:BDX) has become a founding sponsor of a new Medicinal Hazard Data Standardization Consortium focused on hazardous drug information. The global initiative aims to create standardized Medicinal Hazard Data Sheets to reduce data fragmentation and support safer handling of hazardous medicines for healthcare workers. Several major healthcare companies are joining BD in the consortium, which is expected to influence future regulatory and clinical best practice...
B of A Securities Maintains Neutral on Becton Dickinson, Raises Price Target to $200
31.08.2026 13:39
B of A Securities analyst Travis Steed maintains Becton Dickinson (NYSE:BDX) with a Neutral and raises the price target from $185 to $200.
Becton Dickinson (BDX) Could Be 1% Overvalued As PREVENT Trial Enrollment Ends
22.08.2026 00:10
Becton Dickinson (BDX) is in focus after announcing completion of patient enrollment in its PREVENT clinical trial for Phasix Mesh, a potential first in class option for preventing incisional hernias. See our latest analysis for Becton Dickinson. The PREVENT milestone comes after a series of recent updates around Becton Dickinson, including new quality leadership appointments, conference appearances and a recall-related correction notice. It also comes against a backdrop of a 30 day share...
Becton, Dickinson And Co. Completes Enrollment In PREVENT Clinical Trial Evaluating Phasix Mesh For Prevention Of Incisional Hernias
12.08.2026 06:54
Enrollment completed in the first large-scale randomized study evaluating Phasix™ Mesh for incisional hernia prevention, a significant unmet need following abdominal surgeryFRANKLIN LAKES, N.J., Aug. 12, 2026
Becton Dickinson (BDX) Stock Sees Modest Fair Value Lift After Mixed Analyst Views
09.08.2026 05:10
Becton Dickinson has seen its analyst fair value estimate move from US$181.23 to US$189.58, signaling a refreshed price target framework that investors are watching closely. This shift reflects how recent research is weighing the solid fiscal Q3 beat, product updates, and mixed views on 2027 utilization and margin risk. As you read on, you will see how these moving pieces shape the evolving narrative around Becton Dickinson and what that could mean for your own assessment of the stock. Stay...
Why Becton Dickinson (BDX) Is Up 6.8% After Q3 Beat And GLP-1 Delivery Partnerships
09.08.2026 00:20
Becton, Dickinson and Company recently reported third-quarter fiscal 2026 results, with sales rising to US$4,983 million while net income fell to US$377 million, and modestly raised its full-year outlook for low single-digit plus GAAP revenue growth. Alongside these earnings, BD highlighted strong momentum in biologic drug delivery and GLP-1–related partnerships, including a new semaglutide pen collaboration with EMS in Brazil, underscoring the growing role of its Vystra Injection Pen...
Becton Dickinson & Co (BDX) (Q3 2026) Earnings Call Highlights: Strong Revenue Growth and ...
08.08.2026 03:04
BDX beats expectations with 4.4% FX-neutral revenue growth, raises full-year EPS guidance, and outlines strategic plans to navigate fiscal 2027 headwinds.
Becton, Dickinson and Company Q3 Earnings Call Highlights
08.08.2026 00:04
Becton, Dickinson and Company (NYSE:BDX) reported third-quarter fiscal 2026 revenue of $5 billion, up 4.4% on an FX-neutral basis, as growth across its key platforms and operational productivity helped results exceed the company’s expectations. Chairman, Chief Executive Officer and President Tom Po
Wells Fargo Maintains Equal-Weight on Becton Dickinson, Raises Price Target to $170
07.08.2026 09:52
Wells Fargo analyst Lawrence Biegelsen maintains Becton Dickinson (NYSE:BDX) with a Equal-Weight and raises the price target from $161 to $170.
Becton Dickinson (BDX) Q3 Earnings and Revenues Surpass Estimates
06.08.2026 12:20
Becton Dickinson (BDX) delivered earnings and revenue surprises of +2.87% and +1.81%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Becton Dickinson (NYSE:BDX) Reports In-Line Fiscal Q3 Results
06.08.2026 11:29
BD's fiscal Q3 revenue of $4.983B and EPS of $3.23 edged past consensus, leaving results in line with expectations; shares ticked up modestly pre-market.
BD Reports Third Quarter Fiscal 2026 Financial Results
06.08.2026 10:30
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 third quarter, which ended June 30, 2026.
Becton, Dickinson and Company 2026 Q3 - Results - Earnings Call Presentation
06.08.2026 08:35
2026-08-06. The following slide deck was published by Becton, Dickinson and Company in conjunction with their 2026 Q3 earnings call.
Countdown to Becton Dickinson (BDX) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
04.08.2026 13:15
Evaluate the expected performance of Becton Dickinson (BDX) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Waters Exceeds Second-Quarter Forecasts as Broad-Based Growth Continues
04.08.2026 12:22
Waters Corporation (NYSE:WAT) reported second-quarter 2026 results that came in ahead of Wall Street expectations, supported by strong organic growth across its pharmaceutical and industrial businesses. The analytical instruments and diagnostics company’s shares were little changed in pre-market trading, edging up 0.
Henry Schein (HSIC) Q2 Earnings and Revenues Beat Estimates
04.08.2026 11:10
Henry Schein (HSIC) delivered earnings and revenue surprises of +4.10% and +2.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?